NCT03795610View on ClinicalTrials.gov

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

December 22, 2022

Study Completion Date

August 24, 2023

Conditions

Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead and Neck CarcinomaHead and Neck Cancer Stage IVHead and Neck Cancer Stage IIIHPV-Related CarcinomaHPV-Related MalignancyHPV-Related Squamous Cell Carcinoma

Interventions

DRUG

IPI-549

40mg by mouth (PO) every day (QD) for at least 14 days

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors

collaborator

The V Foundation for Cancer Research

OTHER

lead

Assuntina G. Sacco, MD

OTHER

NCT03795610 - IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter